I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Nanotechnology is emerging as a promising tool to restore, maintain, or enhance tissue and organ functions.\[[@ref1][@ref2][@ref3]\] Nanoparticles have been widely applied to produce material structures that mimic biological functions or serve as drug delivery vehicles.\[[@ref4][@ref5]\] For instance, the rare-earth-doped nanoparticles are attractive candidates in nanomedicine, owing to their applications as near-infrared nanoprobes to control cell growth or biomaterial degradation.\[[@ref6][@ref7][@ref8]\] For safety and efficiency of these particles, much attention has been paid to the toxicological evaluation of rare-earth nanomedicine in biological systems.\[[@ref9]\] In previous studies, various toxicity assays were conducted using the nanoparticles coated with peptides, ligands, or other chemical compounds.\[[@ref10][@ref11][@ref12][@ref13][@ref14]\] Surface coating may influence the dimensions, morphologies, and properties of the nanoparticles and lead to potential misunderstanding with respect to their toxicity in response to the ionic leakage in the body.\[[@ref15]\] Therefore, the applications of these nanoparticles in nanomedicine demand a systemic investigation of their cellular toxicity *in vivo*.

Rare-earth-doped nanoparticles without surface protection were recently shown to exhibit potential cytotoxicity, owing to their ability to induce ATP quenching upon binding to the phosphate group of intracellular ATP.\[[@ref16]\] In addition, Maria *et al*.\[[@ref17]\] found that bare rare-earth nanoparticles (RENPs) are toxic to hippocampal cells *in vitro*. So far, most reported studies have focused on the *in vitro* toxicity assays; however, the fate of RENPs circulating in the blood vessels and tissues *in vivo* is much more complicated. Therefore, *in vivo* studies are desirable to accurately assess the toxicity of these nanoparticles.

In this study, we present a systemic investigation for *in vivo* evaluation of hepatotoxicity, nephrotoxicity, and fate in blood circulation of bare RENPs in mice. Two different RENPs were intravenously injected into the mice, and their toxicity was studied by the combination of biochemical analysis and magnetic resonance imaging (MRI) \[[Figure 1a](#F1){ref-type="fig"}\]. We demonstrated that the RENPs cause obvious inflammation-related effects in the mouse, possibly related to ATP quenching effects such that the ATP molecules lose their functions by the strong binding interaction between the phosphate group and rare-earth ions \[[Figure 1b](#F1){ref-type="fig"}\]. Our study on the intrinsic toxicity of these nanoparticles may offer a valuable theoretical basis for evaluation of the toxicity of rare-earth nanomaterials used regenerative medicine.

![(a) A schematic representation of RENPs intravenously injected in the mouse. (b) The injected rare-earth nanoparticles may induce ATP quenching and inflammation in the mouse. ATP quenching was caused by the strong binding interaction between its phosphate group and rare-earth ions. RENPs: Rare-earth nanoparticles.](CMJ-131-1591-g001){#F1}

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

Chemicals {#sec2-1}
---------

The compounds 1-octadecene (90%), oleic acid (90%), Y(CH~3~ CO~2~)~3~⋅H~2~O (99.9%), Gd(CH~3~ CO~2~)~3~⋅H~2~O (99.9%), Er(CH~3~ CO~2~)~3~⋅H~2~O (99.9%), Yb(CH~3~ CO~2~)~3~⋅4H~2~O (99.9%), ammonium fluoride (NH~4~F, 99%), and sodium hydroxide (NaOH, 98%) were purchased from Sigma-Aldrich, Shanghai, China. Isoflurane anesthesia was purchased from Baxter, USA.

Synthesis of rare-earth nanoparticles {#sec2-2}
-------------------------------------

RENPs of NaGdF~4~:Yb/Er (18/2%) and NaYbF~4~:Er (2%) were synthesized with a co-precipitation method, with some modifications in our previously reported protocol.\[[@ref18]\] In brief, an aqueous solution (2 ml) of 0.2 mol/L Gd (CH~3~ CO~2~)~3~, 0.2 mol/L Er (CH~3~ CO~2~)~3~, and 0.2 mol/L Yb (CH~3~ CO~2~)~3~ was prepared in a 50 ml two-neck flask. Oleic acid (3 ml) and octadecene (7 ml) were injected into the flask, and the resulting mixture was heated at 150°C for 2 h under an oil bath condition. The precursor was cooled to 50°C and moved to the heating mantle with a temperature controller. A fresh mixture of 2 ml NaOH (0.5 mol/L in methanol) and 4 ml NH~4~F (0.4 mol/L in methanol) was added, and the resultant mixture was stirred for 2 h, a step that is essential to prepare uniform RENPs. The solution was heated to 100°C and degassed with argon for 30 min to remove the methanol and oxygen. The resultant solution was finally heated to 290°C for 2 h. The product was cooled to room temperature, and the synthesized nanoparticles were precipitated out with ethanol. The nanoparticles were collected by 1680 ×g centrifugation for 10 min, rewashed with ethanol, and finally dispersed in 4 ml of cyclohexane. The preparation of bare RENPs was conducted with a ligand-free method as previously reported.\[[@ref18]\]

Physical characterization of rare-earth nanoparticles {#sec2-3}
-----------------------------------------------------

Luminescence spectra of the RENPs were measured following excitation with a 980 nm diode laser (FC-980, Changchun Optics, China) using a phosphorescence spectrometer (FSP920, Edinburgh, UK). Transmission electron microscopy (TEM) measurements were performed on a 200 kV JEM-2100F transmission electron microscope (JEOL, Japan). Nanoparticle hydrodynamic size and zeta potential were measured using dynamic light scattering (DLS) on a Zetasizer Nanoparticle analyzer series (Malvern Instruments Ltd., England).

Intravenous injection of rare-earth nanoparticles in mice {#sec2-4}
---------------------------------------------------------

The animal study was approved by the Institutional Animal Care and Use Committee of the University. Every effort was made to reduce the suffering of animals and minimize their number. All procedures involved in this study were in accordance with our institutional guidelines that complied with the international ethics for animal use. In our experiment, adult male Institute of Cancer Research (ICR) mice (weight, 20--25 g; age: 6--8 weeks) were purchased from the Laboratory Animal Center of Fujian Medical University (Batch number: SCXK (Viet) 2012-0001). Mice were maintained in a 12 h light/dark environment and provided with food and water. The mice were acclimatized for 1 week before the experiment. RENPs (NaGdF~4~:Yb/Er or NaYbF~4~:Er-based nanoparticles) were intravenously injected at doses of 0, 0.5, 1.0, and 1.5 mg/kg body weight. The mice were weighed daily before receiving an intravenous injection. The symptoms were observed and recorded carefully for 28 days.

Blood biochemical assay {#sec2-5}
-----------------------

The blood samples obtained from ICR mice were used for biochemical analysis. To minimize pain in the experimental animals, mice were given a general anesthetic using 20% urethane, and the blood was withdrawn through the abdominal artery after 7, 14, and 28 days. The serum was obtained by the centrifugation of whole blood at 3000 r/min for 15 min and analyzed using the automatic blood analyzer. During the experiments, all animals received humane care according to the criteria outlined in the "Guide for the Care and Use of Laboratory Animals" prepared by China Government.

Magnetic resonance imaging characterization {#sec2-6}
-------------------------------------------

*In vivo* MRI of mice livers was conducted using a 7 T, 20 cm bore magnet (70/20 USR Bruker, Germany) after intravenous administration of nanoparticles every morning for 7 days. Mice were maintained under isoflurane anesthesia (1.2% ± 0.5%) throughout imaging and were placed in a prone position on an animal bed and then slide in the center of a magnet bore. The parameters were as follows: *T~2~* mapping was acquired using MSME\_*T~2~* (Multi-Slice Multi Echo) sequence (repetition time \[TR\] = 0.5 s, effective echo time \[TE\] = 17.0 ms, field of view = 30.00 × 30.00 mm). Images were reconstructed at 100 μm isotropic resolution, while the acquisition time was \~1 h.

Statistical analysis {#sec2-7}
--------------------

Experiments were repeated at least thrice (*n* ≥ 3), and each group in the behavior studies had at least ten mice. Data are expressed as mean ± standard deviation (SD) and analyzed with the analysis of variance (ANOVA) followed by a one-way ANOVA test. A repeated measures\' analysis was used to determine any significant differences in white blood cell (WBC), alanine aminotransferase (ALT), and creatinine (CREA) levels at different evaluation times in each group. Statistical analysis was performed with SPSS 19.0 software (SPSS Inc., Chicago, IL, USA). Significance was set at *P* ≤ 0.05.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Characterization of rare-earth nanoparticles {#sec2-8}
--------------------------------------------

To examine the effects of particle size on toxicity in mice, two different sizes of RENPs were synthesized. In a typical experiment, the size of the RENPs was adjusted by controlling Yb^3+^ dopant concentration in the host. The resulting RENPs were characterized with TEM. As shown in Figure [2a](#F2){ref-type="fig"} and [2b](#F2){ref-type="fig"}, the size of the NaGdF~4~:Yb/Er and NaYbF~4~:Er RENPs was 10 nm and 100 nm, respectively. Furthermore, fluorescence spectra were measured at an excitation of 980 nm diode laser \[Figure [2c](#F2){ref-type="fig"} and [2d](#F2){ref-type="fig"}\]. These results demonstrated the successful preparation of the desired RENPs. For their application in mice, the synthesized hydrophobic nanoparticles were made hydrophilic with ligand-free method. In addition, we measured the zeta potential and hydrodynamic size in a dispersion medium to study the dispersion of these particles in solution. As shown in [Figure 2e](#F2){ref-type="fig"}, the prepared nanoparticles are well dispersed in cell culture media after a ligand-free treatment. The measurement of zeta potential further showed that the bare rare-earth-doped nanoparticles had positive charges on their surfaces \[[Figure 2f](#F2){ref-type="fig"}\], suggestive of their ability to interact with the phosphate group of intracellular ATP.

![(a and b) Low-resolution TEM image of the synthesized nanoparticles with different rare-earth dopants. NaGdF4:Yb/Er (18/2) and NaYbF4:Er (2% mol). (c and d) Luminescence emission spectra of nanoparticles with different rare-earth dopants in cyclohexane. NaGdF4:Yb/Er (18/2) and NaYbF4:Er (2% mol). The spectra were recorded after excitation with a 980 nm laser. (e) Dynamic light scattering measurement of the rare-earth nanoparticles dispersed in cell culture media. (f) Zeta potential of NaGdF4:Yb/Er (18/2) nanoparticles dispersed in water. TEM: Transmission electron microscopy.](CMJ-131-1591-g002){#F2}

*In vivo* magnetic resonance imaging for nanoparticle uptake evaluation {#sec2-9}
-----------------------------------------------------------------------

To study the uptake of RENPs, mice were intravenously injected with bare RENPs on every morning for 7 days. To observe the nanoparticle circulation in the mice, MRI was carried out to study the RENPs present in the mouse liver. As shown in [Figure 3](#F3){ref-type="fig"}, distinct T2 hyperintense signals were detected in the mouse liver. Our results showed that the MRI signals in mice liver were enhanced after 1 h of injection, and the signal intensity disappeared after 3 h. This result suggests that the RENPs may be uptaken in the liver, followed by their clearance from the liver. The dynamic observation of the RENPs may help us better understand the metabolism pathway of the nanoparticles in the animal body.

![T2-weighted images of mice liver as a function of time after rare-earth nanoparticle injection. The MRI images (a-d) were recorded after 0.5, 1, 2, and 3 h, respectively. The white arrows indicated the evidence of the rare-earth nanoparticles uptaken in the liver of the mouse. MRI: Magnetic resonance imaging.](CMJ-131-1591-g003){#F3}

Hematological analysis for toxicological evaluation {#sec2-10}
---------------------------------------------------

To investigate the effect of RENPs on the mouse, hematological analysis was performed after 7, 14, and 28 days from the injection of bare RENPs. As shown in Figure [4a](#F4){ref-type="fig"}, [4b](#F4){ref-type="fig"} and [Table 1](#T1){ref-type="table"}, mice injected with NaYbF~4~:Er and NaGdF~4~:Yb/Er nanoparticles showed an increased level of WBCs as compared with control mice. Mice injected with a high dose of 1.5 mg/kg NaGdF~4~:Yb/Er nanoparticles (or NaYbF~4~:Er nanoparticles) showed an obvious abnormal change in the level of WBC as compared to those injected with 0.5 and 1.0 mg/kg NaGdF~4~:Yb/Er nanoparticles (or NaYbF~4~:Er nanoparticles). In addition, the level of WBCs in NaYbF~4~:Er treatment group increased as compared to that in NaGdF~4~:Yb/Er treatment group. WBCs, also called as leukocytes, originate in the bone marrow but circulate throughout the bloodstream. Any abnormal change in WBCs levels is suggestive of the occurrence of inflammation following the invasion of the RENPs. This observation may be associated with the presence of rare-earth ions on the surface of bare nanoparticles or ion leakage that resulted in their strong binding to ATP molecules in cells. As a consequence, ATP quenching was observed that resulted in cell apoptosis and autophagy. The clearance of the damaged cells may be likely responsible for the inflammation observed in these mice. Furthermore, the injection of large-sized NaYbF4:Er nanoparticles resulted in higher levels of WBCs as compared to small-sized NaGdF4:Yb/Er nanoparticles under same experimental condition. We suggest that the large RENPs may not be efficiently cleared from the blood system. Further analysis of the red blood cell and platelet levels revealed the absence of any obvious damage caused to the blood function by RENPs.

![(a) ICR mice were subcutaneously injected with different bare rare-earth nanoparticles. Hematological and biochemical analyses were performed to evaluate any impairment in organ functions. (b-d) Effects of rare-earth nanoparticles on WBC, ALT, and CREA levels in ICR mice. The data were acquired on day 7, 14, and 28. \*Comparison between control and groups injected with the same type of nanoparticles at different doses (*P* \< 0.05). ^†^Comparison between groups injected with different nanoparticles at the same dose (*P* \< 0.05). ^‡^Comparison between two groups treated with 0.5 and 1.0 mg/kg rare-earth nanoparticle of the same type (*P* \< 0.05). ^§^Comparison between two groups treated with 1.5 and 1.0 mg/kg rare-earth nanoparticle of the same type (*P* \< 0.05). ^\|\|^Comparison between two groups treated with 1.5 and 0.5 mg/kg of rare-earth nanoparticle of the same type (*P* \< 0.05). ICR: Institute of Cancer Research; WBC: White blood cell; ALT: Alanine aminotransferase; CREA: Creatinine.](CMJ-131-1591-g004){#F4}

###### 

Hematological analysis in mice treated with rare-earth nanoparticles\* (*n* = 10)

  Parameters        Time points    Control        NaGdF~4~:Yb/Er-0.5   NaGdF~4~:Yb/Er-1.0   NaGdF~4~:Yb/Er-1.5   NaYdF~4~:Er-0.5   NaYdF~4~:Er-1.0   NaYdF~4~:Er-1.5
  ----------------- -------------- -------------- -------------------- -------------------- -------------------- ----------------- ----------------- -----------------
  WBC (×10^9^/L)    7^th^          3.02 ± 0.33    4.05 ± 0.29          4.65 ± 0.24          5.52 ± 0.38          6.26 ± 0.22       7.16 ± 0.46       8.81 ± 0.69
  14^th^            3.31 ± 0.19    4.19 ± 0.14    4.56 ± 0.12          5.28 ± 0.29          5.75 ± 0.22          6.55 ± 0.40       7.92 ± 0.83       
  28^th^            2.44 ± 1.09    4.05 ± 0.29    4.89 ± 0.52          6.32 ± 1.57          5.79 ± 0.43          6.72 ± 0.35       8.69 ± 0.85       
  RBC (×10^12^/L)   7^th^          9.87 ± 0.85    9.31 ± 1.04          10.41 ± 0.52         10.10 ± 0.76         9.84 ± 0.90       9.90 ± 0.79       10.16 ± 0.71
  14^th^            10.16 ± 0.80   9.91 ± 0.75    9.24 ± 1.90          9.97 ± 0.64          9.91 ± 0.87          9.77 ± 0.22       10.75 ± 0.20      
  28^th^            9.63 ± 0.70    9.31 ± 1.04    10.42 ± 0.52         9.98 ± 1.23          10.32 ± 0.49         9.76 ± 0.67       9.92 ± 0.42       
  PLT (×10^11^/L)   7^th^          15.60 ± 3.74   15.88 ± 1.30         14.65 ± 1.96         14.36 ± 3.13         16.84 ± 3.78      15.77 ± 2.03      12.89 ± 3.53
  14^th^            14.79 ± 2.29   15.67 ± 2.05   13.83 ± 2.56         14.35 ± 1.75         14.92 ± 2.50         15.37 ± 1.63      14.58 ± 2.56      
  28^th^            12.43 ± 7.06   15.88 ± 1.30   14.78 ± 1.81         16.88 ± 2.60         15.88 ± 3.90         14.23 ± 2.73      12.73 ± 3.21      

\*The data was acquired on day 7, 14, and 28 after injection with rare-earth nanoparticles. RBC: Red blood cell; PLT: Platelet; WBC: White blood cell.

Biochemical analysis for toxicological evaluation {#sec2-11}
-------------------------------------------------

We examined the influence of RENPs on the liver and kidney in mice. Biochemical analysis was carried out to evaluate the toxicity associated with bare RENPs after their injection in mice. In particular, CREA is a waste product indicative of the kidney function and high level of CREA in the blood may reveal the malfunctioning or failure of kidneys. In comparison with the control mice, those injected with a high dose (1.5 mg/kg) of NaGdF4:Yb/Er nanoparticles showed an abnormal change in the level of CREA on day 28 after injection \[[Figure 4c](#F4){ref-type="fig"} and [Table 2](#T2){ref-type="table"}\]. These results suggest that the RENPs only caused minor nephritic toxicity but caused obvious hepatotoxicity in mice, as evaluated by ALT level in mice blood. ALT is an enzyme produced in the liver cells; an increase in serum ALT level is indicative of the damage or inflammation of the liver. As shown in [Figure 4d](#F4){ref-type="fig"} and [Table 2](#T2){ref-type="table"}, mice injected with RENPs (experimental groups) had an obvious increase in ALT levels as compared with the control mice. In comparison with the small-sized NaGdF4:Yb/Er nanoparticles, large-sized NaYbF4:Er nanoparticles caused an obvious increase in ALT levels. This observation could be explained by the enrichment of large-sized nanoparticles in the mice liver that may have caused severe damage to the liver. At day 14, the increase in the total bilirubin level was more prominent, suggestive of an increase in the metabolic disturbance in mouse liver. This result indicates the enhanced clearance of RENPs from the mouse liver by day 14. No obvious variations in the level of aspartate aminotransferase, total proteins, and uric acid were observed. Taken together, bare RENPs exhibited nonnegligible risk upon their direct application in the animal body.

###### 

Effects of rare-earth nanoparticles on biochemical analysis\* (*n* = 10)

  Parameters      Time points      Control          NaGdF~4~:Yb/Er-0.5   NaGdF~4~:Yb/Er-1.0   NaGdF~4~:Yb/Er-1.5   NaYdF~4~:Er-0.5   NaYdF~4~:Er-1.0   NaYdF~4~:Er-1.5
  --------------- ---------------- ---------------- -------------------- -------------------- -------------------- ----------------- ----------------- -----------------
  TBIL (µmol/L)   7^th^            3.96 ± 0.77      4.00 ± 0.81          3.92 ± 0.88          3.78 ± 0.63          4.62 ± 1.00       4.40 ± 0.55       4.18 ± 0.33
  14^th^          4.02 ± 0.94      21.42 ± 5.98     18.58 ± 3.81         16.98 ± 2.98         17.14 ± 6.17         19.50 ± 8.17      15.88 ± 5.25      
  28^th^          3.86 ± 0.82      4.36 ± 0.67      3.76 ± 0.55          3.94 ± 0.88          4.72 ± 0.54          3.94 ± 0.42       4.28 ± 0.98       
  ALT (U/L)       7^th^            32.60 ± 4.51     40.60 ± 1.67         44.60 ± 1.34         50.60 ± 2.07         53.80 ± 0.84      57.60 ± 2.70      73.60 ± 10.21
  14^th^          34.00 ± 1.58     33.40 ± 1.95     42.60 ± 3.85         50.20 ± 1.79         58.40 ± 6.15         72.40 ± 4.22      102.00 ± 33.70    
  28^th^          34.20 ± 6.53     41.20 ± 2.28     45.00 ± 7.10         48.20 ± 3.70         60.80 ± 10.26        59.80 ± 5.85      64.20 ± 15.50     
  AST (U/L)       7^th^            124.60 ± 13.40   141.00 ± 35.92       122.80 ± 14.84       145.60 ± 29.36       154.80 ± 43.27    142.60 ± 18.20    187.80 ± 58.34
  14^th^          119.60 ± 16.74   131.20 ± 13.08   136.00 ± 19.69       145.60 ± 15.77       142.80 ± 30.64       157.80 ± 24.40    197.00 ± 40.04    
  28^th^          116.40 ± 10.09   136.20 ± 38.13   136.80 ± 5.93        133.60 ± 29.59       153.60 ± 16.26       167.40 ± 52.35    175.20 ± 55.11    
  TP (g/L)        7^th^            54.48 ± 0.97     55.76 ± 2.08         54.52 ± 4.72         51.64 ± 3.93         55.04 ± 4.73      56.60 ± 1.54      57.12 ± 4.99
  14^th^          54.00 ± 3.01     52.08 ± 2.28     52.56 ± 1.97         57.84 ± 4.37         45.56 ± 17.14        16.02 ± 1.34      34.00 ± 22.30     
  28^th^          54.24 ± 0.91     57.68 ± 3.14     51.62 ± 2.49         54.94 ± 3.21         57.28 ± 3.18         55.82 ± 4.22      53.58 ± 5.29      
  CREA (µmol/L)   7^th^            22.00 ± 3.53     24.00 ± 4.18         20.60 ± 5.22         27.00 ± 6.16         28.20 ± 2.77      27.20 ± 4.15      24.20 ± 3.35
  14^th^          22.80 ± 4.49     28.00 ± 2.00     27.60 ± 4.93         28.20 ± 5.81         30.60 ± 2.41         27.20 ± 3.03      37.00 ± 3.87      
  28^th^          20.40 ± 3.91     26.60 ± 2.30     24.20 ± 7.69         22.00 ± 3.54         27.20 ± 4.15         25.00 ± 3.61      27.80 ± 3.56      
  URIC (µmol/L)   7^th^            279.80 ± 67.58   299.80 ± 106.21      249.00 ± 87.52       349.40 ± 160.63      410.40 ± 115.27   302.20 ± 50.19    318.00 ± 105.65
  14^th^          243.80 ± 39.98   287.80 ± 73.41   259.80 ± 42.05       289.4 ± 82.99        319.80 ± 84.57       389.00 ± 86.20    393.00 ± 144.26   
  28^th^          206.60 ± 44.24   273.80 ± 52.18   321.40 ± 100.58      300.40 ± 40.07       262.20 ± 77.17       393.80 ± 136.11   450.40 ± 66.76    

\*The data were acquired at day 7, 14, and 28 after injection with rare-earth nanoparticles in mice. TBIL: Total bilirubin; AST: Aspartate aminotransferase; TP: Total proteins; URIC: Uric acid; CREA: Creatinine.

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

In this study, we have performed *in vivo* evaluation of hepatotoxicity and nephritic toxicity caused by two different sizes of RENPs in mice. In previous studies, RENPs\' surface coated with biomolecules, polymers, or silica layers exhibited low cytotoxicity in mice.\[[@ref19][@ref20]\] As the coating material may influence the accurate assessment of the potential toxicity of bare nanoparticles or ionic leakage in mice, the intrinsic cytotoxicity of bare nanoparticles was studied. In this study, we used a hydrophilic ligand-free method to prepare bare RENPs that allowed the study of the intrinsic toxicity of RENPs in the animal body. TEM characterization and fluorescence spectrum measurement revealed the successful synthesis of RENPs. Although it was reported that ligand-free RENPs can induce a decrease in cell viability, possibly associated with the deprivation of intracellular ATP in live cells, few studies are reported to examine the toxic effects of bare RENPs *in vivo*.

The results of the *in vivo* MRI characterization study demonstrated the distribution and circulation of the RENPs in the liver. The biochemical analysis of serum samples further indicated the physiological and pathological damage caused to mice organs and tissues, particularly liver and kidney, by RENPs. It is well known that liver and kidney are the main organs to metabolize endogenous or exogenous agents and serve as the sites for cholesterol synthesis and degradation.\[[@ref21][@ref22]\] The levels of some enzymes and substances such as ALT and CREA may directly reflect the functional statuses of these organs.\[[@ref23]\] The biochemical analysis of serum revealed the adverse effects of RENPs on the liver and kidney of experimental mice, particularly those injected with 1.5 mg/kg NaYbF~4~:Er nanoparticles.

The increase in the number of WBCs was indicative of inflammation in the mouse body that may probably cause fever or hematologic disease after particle injection.\[[@ref23]\] Therefore, we suggest that the injected RENPs were mainly transported in the blood and metabolic organs such as the liver and kidney, which may explain how these particles induced injuries to the kidney and liver in our experiment.

Although our study has suggested that the use of RENPs may cause hepatotoxicity and nephritic toxicity in the animal, many strategies have been developed to minimize or avoid the risk of nanoparticles such as a surface coating of particles with silica, polymer, or proteins.\[[@ref24][@ref25][@ref26][@ref27]\] The direct interaction between nanoparticles (or rare-earth ions) and molecules in the cells may be mitigated through the use of these approaches. The rapid development of nanotechnology may facilitate progress in the field of nanomedicine and other biomedical applications. Considering the practical applications of nanomedicine, the results of the present study may provide a noteworthy explanation to understand the application of nanotechnology for future medical development.

In conclusion, our study has revealed the fact of obvious injuries to mouse liver and kidneys caused by the bare RENPs. The findings presented in this work may provide a fundamental understanding of the intrinsic toxicity associated with bare RENPs in animals. Moreover, our study would improve the understanding of the effects of long-term and high-dose treatment of RENPs on different organs.
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